Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
84.71
+1.99 (2.41%)
Aug 4, 2026, 1:27 PM EDT - Market open
Inhibrx Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 161.66 | 124.22 | 152.6 | 277.92 | 273.87 | 131.3 |
Cash & Short-Term Investments | 161.66 | 124.22 | 152.6 | 277.92 | 273.87 | 131.3 |
Cash Growth | -25.34% | -18.60% | -45.09% | 1.48% | 108.58% | 2.05% |
Accounts Receivable | - | - | 0.2 | 0.78 | 0.24 | 0.37 |
Other Receivables | 0.19 | 0.18 | 0.22 | - | 0.01 | 0.51 |
Total Trade Receivables | 0.19 | 0.18 | 0.42 | 0.78 | 0.26 | 0.88 |
Other Current Assets | 9.5 | 8.44 | 7.38 | 16.66 | 6.37 | 6.93 |
Total Current Assets | 171.34 | 132.83 | 160.4 | 295.36 | 280.49 | 139.11 |
Net Property, Plant & Equipment | 8.25 | 9.27 | 13.54 | 9.37 | 7.22 | 9.49 |
Other Long-Term Assets | 4.38 | 4.38 | 6.83 | 3.16 | 3.16 | 1.85 |
Total Assets | 183.97 | 146.48 | 180.77 | 307.89 | 290.88 | 150.45 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.76 | 5.94 | 9.25 | 10.95 | 8.33 | - |
Accrued Expenses | 15.34 | 25.53 | 29.89 | 43.3 | 17.22 | 9.62 |
Current Portion of Leases | 2.41 | 2.33 | 1.6 | 2.06 | 1.86 | 1.67 |
Unearned Revenue | - | - | - | - | 0.17 | 2.03 |
Total Current Liabilities | 26.51 | 33.8 | 40.73 | 56.31 | 27.58 | 22.45 |
Long-Term Debt | 174.99 | 100.56 | - | 206.97 | 202.07 | 70.47 |
Long-Term Leases | 3.5 | 4.13 | 6.45 | 1.11 | 3.17 | 5.03 |
Other Long-Term Liabilities | - | - | - | - | - | 0.11 |
Total Long-Term Liabilities | 178.49 | 104.69 | 6.45 | 208.08 | 205.24 | 75.61 |
Total Liabilities | 205 | 138.49 | 47.18 | 264.39 | 232.82 | 98.07 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0.01 | 0 | 0 |
Additional Paid-in Capital | 258.59 | 254.18 | 239.72 | 657.23 | 430.43 | 279.53 |
Retained Earnings | -279.63 | -246.19 | -106.13 | -613.73 | -372.37 | -227.15 |
Shareholders' Equity | -21.04 | 7.99 | 133.58 | 43.5 | 58.06 | 52.38 |
Total Liabilities & Equity | 183.97 | 146.48 | 180.77 | 307.89 | 290.88 | 150.45 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 180.9 | 107.01 | 8.05 | 210.14 | 207.1 | 77.18 |
Net Cash (Debt) | -19.24 | 17.21 | 144.55 | 67.78 | 66.76 | 54.12 |
Net Cash Growth | - | -88.09% | 113.25% | 1.53% | 23.35% | -40.66% |
Net Cash Per Share | -1.24 | 1.11 | 9.65 | 5.75 | 1.67 | 1.42 |
Book Value | -21.04 | 7.99 | 133.58 | 43.5 | 58.06 | 52.38 |
Book Value Per Share | -1.36 | 0.52 | 8.92 | 3.69 | 1.45 | 1.38 |
Tangible Book Value | -21.04 | 7.99 | 133.58 | 43.5 | 58.06 | 52.38 |
Tangible Book Value Per Share | -1.36 | 0.52 | 8.92 | 3.69 | 1.45 | 1.38 |